» Articles » PMID: 29564555

Treatment Patterns in Patients with Osteoporosis at High Risk of Fracture in Japan: Retrospective Chart Review

Overview
Journal Arch Osteoporos
Publisher Springer
Date 2018 Mar 23
PMID 29564555
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The incidence of osteoporosis (OP) in Japan is predicted to increase significantly in coming decades. Resultant osteoporotic fractures are a significant contributor of economic and social burden among elderly osteoporosis patients. This retrospective chart review was conducted as a response to the current evidence gap in the treatment patterns for OP patients with high risk of fracture in Japan.

Methods: This was a multi-centre retrospective chart review that analysed data extracted from the medical records of postmenopausal OP patients at high risk for fracture who received care at 11 specialist clinics and medical centers in Japan for at least 18 to 24 months. Main outcome was OP treatment patterns.

Results: The study included 709 eligible patients of whom 623 (87.9%) were prescribed OP medication during the study period. The most common reason for not taking OP medication was patient unwillingness to take medication. The most common OP medications prescribed initially were minodronic acid (20.1%), alendronate (19.9%), raloxifene (14.1%), weekly teriparatide acetate (12.4%) and eldecalcitol (11.4%). Majority of patients (62.1%) were still taking their initial medication at the end of the 18-24 month follow-up.

Conclusions: A high percentage of patients (87.9%) in Japan received OP medications soon after their high-risk diagnosis, with bisphosphonates, selective estrogen receptor modulators and teriparatide being the predominant treatment options.

Citing Articles

Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021.

Soen S, Wang A, Hamaya E, Chien H, Lin T J Bone Miner Metab. 2024; 42(6):653-667.

PMID: 38987505 PMC: 11631996. DOI: 10.1007/s00774-024-01530-6.


BMP2-ERK-ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis.

Zhou Z, Zhao C, Li S, Han X, Zhu J, Xue S Int J Mol Sci. 2024; 25(6).

PMID: 38542323 PMC: 10970383. DOI: 10.3390/ijms25063350.


Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.

Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K J Bone Miner Metab. 2023; 42(1):77-89.

PMID: 38086988 DOI: 10.1007/s00774-023-01477-0.


Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis.

Ri K, Fukasawa T, Masuda S, Tanaka S, Takeuchi M, Yoshida S J Bone Miner Metab. 2023; 41(6):890-900.

PMID: 37897673 DOI: 10.1007/s00774-023-01470-7.


A real-world study of treatment patterns among patients with osteoporotic fracture: analysis of a Japanese hospital database.

Hagino H, Yoshinaga Y, Hamaya E, Lin T, Ajmera M, Meyers J Arch Osteoporos. 2023; 18(1):23.

PMID: 36683098 PMC: 9868038. DOI: 10.1007/s11657-022-01201-x.